Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1981 2
1983 3
1984 4
1985 4
1986 70
1987 319
1988 410
1989 500
1990 779
1991 1044
1992 1804
1993 2294
1994 2909
1995 3446
1996 3550
1997 4020
1998 4023
1999 4368
2000 4743
2001 4951
2002 5142
2003 4544
2004 4359
2005 3895
2006 3892
2007 3516
2008 3510
2009 3880
2010 3470
2011 3393
2012 3094
2013 2743
2014 2622
2015 2640
2016 2299
2017 2314
2018 1625
2019 682
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

91,079 results
Results by year
Filters applied: . Clear all
Page 1
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.
Murer P and Neri D. N Biotechnol 2019 - Review. PMID 30991144 Free PMC article.
Antibody-cytokine fusion proteins represent a novel class of biopharmaceuticals, with the potential to increase the therapeutic index of cytokine 'payloads' and to promote leukocyte infiltration at the site of disease. ...Moreover, by using anti-inflammatory cytokines, antibody fusion strategies can conveniently be employed for the treatment of auto-immune and chronic inflammatory conditions....
Antibody-cytokine fusion proteins represent a novel class of biopharmaceuticals, with the potential to increase the therapeuti …
CUT&Tag for efficient epigenomic profiling of small samples and single cells
Kaya-Okur HS, et al. Nat Commun 2019. PMID 31036827 Free PMC article.
In CUT&Tag, a chromatin protein is bound in situ by a specific antibody, which then tethers a protein A-Tn5 transposase fusion protein. ...
In CUT&Tag, a chromatin protein is bound in situ by a specific antibody, which then tethers a protein A-Tn5 transposase fusion pr …
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
Mortara L, et al. Front Immunol 2018 - Review. PMID 30619269 Free PMC article.
Antibody-cytokine fusion proteins (immunocytokine) exert a potent anti-cancer effect; indeed, they target the immunosuppressive tumor microenvironment (TME) due to a specific anti-tumor antibody linked to immune activating cytokines. ...
Antibody-cytokine fusion proteins (immunocytokine) exert a potent anti-cancer effect; indeed, they target the immunosuppressiv …
Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model
Zhong L, et al. Nat Commun 2019. PMID 30911003 Free PMC article.
To gain insights into the pathological roles of sTREM2, we studied sTREM2 in the brain of 5xFAD mice, a model of AD, by direct stereotaxic injection of recombinant sTREM2 protein or by adeno-associated virus (AAV)-mediated expression. ...
To gain insights into the pathological roles of sTREM2, we studied sTREM2 in the brain of 5xFAD mice, a model of AD, by direct stereotaxic i …
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
Yang W, et al. Nat Med 2019. PMID 31011208 Free PMC article.
Using whole-genome sequencing and RNA sequencing, we identified a novel gene fusion and demonstrated that it produces a neoantigen that can specifically elicit a host cytotoxic T cell response. ...Finally, analyzing additional datasets of fusion-positive cancers, including checkpoint-inhibitor-treated tumors, we found evidence of immune surveillance resulting in negative selective pressure against gene fusion-derived neoantigens. ...
Using whole-genome sequencing and RNA sequencing, we identified a novel gene fusion and demonstrated that it produces a neoantigen th …
Design of split superantigen fusion proteins for cancer immunotherapy.
Golob-Urbanc A, et al. J Biol Chem 2019. PMID 30782846 Free PMC article.
To overcome the limitation of conventional antibody-superantigen fusion proteins, we have split a superantigen into two fragments, individually inactive, until both fragments came into close proximity and reassembled into a biologically active form capable of activating T cell response. ...This design selectively activated T cells by split SEA-scFv fusion binding to target cells....
To overcome the limitation of conventional antibody-superantigen fusion proteins, we have split a superantigen into two fragme …
91,079 results
Jump to page
Feedback